XML 45 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
12 Months Ended
Jun. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events

Note 12 – Subsequent Events

 

On July 31, we made the second payment towards an asset purchase totaling $300,000.

 

Our board of directors approved a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding, which was effected on August 10, 2018. This adjustment is reflected in this Annual Report.

 

In August, the Aytu sales force began promotions of ZolpiMist to U.S. clinicians.

 

On September 5, 2018, Aytu and Magna Pharmaceuticals, Inc. agreed to amend and restate the license agreement effective as of June 11, 2018.